原发性肝癌患者乙型肝炎病毒感染状况

对６４例ＡＦＰ＞４００μＧ／Ｌ原发性肝癌（ＰＨＣ）患者与ＡＦＰ＜５０μｇ／Ｌ１５６例非ＰＨＣ者进行ＨＢＶ标志物检测。结果表明：１．ＨＰＣ患者合并ＨＢＶ感染者远远多于无ＰＨＣ者ＨＢｓＡｇ阳性率为８２．８％，对照组ＨＢｓＡｇ阳性主继７．６９％，ＰＨＣ病例ＨＢＶ流行率显著高于对照组Ｐ＜０．０１，有慢性肝炎病史者为ＰＨＣ高危对象。２．ＰＨＣ患者男性多于女性。     

乙型肝炎病毒感染与肝细胞性肝癌相关性的研究

目的探讨乌鲁木齐地区维族汉族乙型肝炎病毒感染与肝癌关系。方法322例肝细胞性肝癌患者（其中维族150例,汉族172例）进行乙型肝炎病毒感染及ALT、AST、CA125、CA199、AFP的检测,并进行比较。结果HBsAg（＋）254例,其中维族阳性率77．3％（116例）与汉族阳性率80．2％（138例）,差异无统计学意义。维族汉族肝癌患者ALT和AST的值分别为（845．57±54．25）,（1382．36±125．34）和（798．85±69．17）,（1405．82±151．2）,差异均有统计学意义（P〈0．05）。维族汉族肝癌患者血清CA125、CA199、AFP差异均无统计学意义。结论乌鲁木齐地区肝癌患者血清乙型肝炎病毒感染率较高,可能是维族汉族肝癌的主要病原学因素。     

广西肝癌低发区HBV、HCV感染与肝细胞癌关系的对照研究

乙型肝炎病毒 (ＨＢＶ)、丙型肝炎病毒 (ＨＣＶ)是引起慢性肝炎的主要病原体。ＨＣＶ感染者 80 %可发展为慢性肝炎 ,部分患者进而可发展成为肝硬化和肝细胞癌 (ＨＣＣ)。研究证实 ,ＨＣＶ是日本和西方国家肝癌发生的主要危险因素之一。而对我国肝癌高发区进行研究结果表明 ,ＨＢＶ感染是ＨＣＣ发生的主要病因 ,但目前ＨＢＶ、ＨＣＶ导致肝细胞癌的机制尚不清楚。为了探讨ＨＢＶ、ＨＣＶ与原发性肝癌发生的关系 ,我们在广西肝癌低发区进行了对比研究 ,现将结果报告如下。1　资料与方法1 .1　研究对象　本研究选择来自广西肝癌低发区 (15 / 10…     

血清AFP、GP73水平检测对非肝癌慢性HBV感染者的临床价值

目的探讨血清甲胎蛋白(AFP)、高尔基体糖蛋白-73(GP73)检测对非肝癌慢性乙型肝炎病毒(HBV)感染者的临床价值。方法将中国科技大学附属第一医院2017年1月至2019年6月收治的非肝癌慢性HBV感染者157例纳入研究;根据慢性HBV感染的类型分为慢性乙型肝炎(CHB)肝硬化失代偿期组40例、CHB肝硬化代偿期组44例、CHB组43例、HBV携带者组30例;另外,选取同期体检合格的健康者30例作为健康组。检测上述人群血清AFP、GP73水平并进行组间比较;采用受试者工作特征(ROC)曲线进行分析,得出AFP、GP73单项和联合检测用于诊断CHB肝硬化失代偿期的灵敏度、特异度及准确度。结果 CHB肝硬化失代偿期组血清AFP水平高于健康组(P0.05),与其他各组比较无差异无统计学意义(P0.05);各组间GP73水平两两比较差异均有统计学意义(P0.05),水平由低至高依次为HBV携带者组、CHB组、CHB肝硬化代偿期组、CHB肝硬化失代偿期组。AFP和GP73联合检测ROC曲线下面积最大,为0.813,特异度为96.60%,准确度为83.42%。结论血清AFP、GP73水平能为肝硬化失代偿期的诊断和HBV感染者病情判断提供参考。     

HBV耐药与肝癌临床相关性分析

乙型肝炎病毒（HBV）是导致慢性肝病和原发性肝细胞癌（以下简称肝癌）的最主要病因。报道HBV变异与耐药的文献较多,但少有结合临床资料阐述HBV耐药与肝癌的发病关系。作者选择63例肝癌患者,根据其病变基础分成慢性乙型肝炎组和肝硬化组,比较其生化指标、HBV基因、耐药变异、肿瘤标记物等,旨在探讨HBV变异、抗病毒药物应用与肝癌发生的可能相关性,以期在临床中择优选用抗病毒药物。     

血浆Dickkopf同源物1检测对肝细胞癌的诊断价值

目的 探讨检测血浆Dickkopf同源物1(DKK1)对肝细胞癌(HCC)的诊断价值。方法 选取2014年11月～2015年12月南通市第三人民医院已确诊的HCC患者48例,肝硬化(LC)20例,慢性乙型肝炎(CHB)20例,选择排除其他慢性疾病的健康体检者(HC)20例,采用ELISA方法定量检测血浆中DKK1浓度,同时采用美国雅培i2000微粒子化学发光免疫分析仪检测其AFP。同时比较分析其ROC曲线及相关性。结果 HCC组DKK1水平均显著高于LC组、CHB组和HC组(Z=-4.132～-5.828,P均<0.001)。DKK1对HCC诊断价值的ROC曲线下面积为0.889,95%置信区间为0.831～0.947,DKK1诊断HCC最佳cutoff值为565 ng/L,其诊断灵敏度为93.8%,特异度为70%,AFP的ROC曲线下面积为0.759,95%置信区间为0.667～0.850。DKK1的AUC显著>AFP(Z=2.28,P=0.022)。DKK1和AFP两指标间无相关性(r=0.148,P=0.316),其中有21例AFP<20 μg/L而其DKK1>565 ng/L的诊断临界值。结论 检测血浆中DKK1可以作为AFP诊断HCC的有效补充,尤其是DKK1对AFP阴性HCC患者的早期诊断价值值得关注。     

原发性肝细胞癌HBV、HCV感染状况的分析

为了探讨HCC与HBV、HCV感染的关系 ,了解HCC中HBV、HCV感染的构成 ,我们对 38例HCC及46例非肝癌癌症患者进行了HBV、HCV感染状况的研究。HCC及非肝癌癌症患者的HBV感染率分别为 78.95 %(30/38)、13.04 % (6/46 ) ,χ2 =36.90 ,P 2 =4.5 ,P <0.05。在原发性肝癌患者中A(“大三阳”)、B(“小三阳”)及C(HBsAg兼HBcAb双阳性 )这三种模式的检出率分别为 15.79% ,28.5 9% ,26.32 % ,但这三种模式在非肝癌癌症患者中均未出现 ,两组间有高度显著性差异。其中HBeAg均为阴性的检出率为 55.26%远高于HBeAg阳性者。HCC患者中 ,单纯乙肝感染者、单纯丙肝感染者、乙、丙肝混合感染者的构成分别为 41.18%、11.76%、47.06 %。以上结果提示 ,HCC的发生和HBV的感染有密切的关系 ;单纯HBV感染、HBV及HCV混合感染比单纯HCV感染者发生HCC的可能性大 ,但也并不说明单纯HCV感染者就没有发生HCC的危险性。     

鲁南地区HBV基因型和HBV核心启动子双点突变与肝硬化、肝癌的关系

目的研究鲁南地区肝细胞癌(HCC)、肝硬化(LC)患者与乙型肝炎病毒(HBV)基因型及基本C区启动子(BCP)基因区A1762T/G1764A双位点变异之间的关系,探讨其相关性。方法按慢性HBV感染者111例的不同临床分型,对其中HCC、LC和慢性乙型肝炎(CHB)患者各37例,采用实时荧光定量PCR法及PCR微板核酸杂交ELLSA技术进行HBV基因定量、分型检测;采用HBV基因多态性芯片检测BCP区A1762T/G1764A双位点变异;对不同性别、年龄、病毒基因型分布、临床分型患者进行HBV基因分型、BCP区双突变,以及不同HBV基因型BCP双突变的比较。结果在CHB、LC、HCC患者中,HBeAg阴性者分别为24.3%、75.7%和83.8%;HCC患者HBeAg阴性率较CHB患者明显升高(P<0.05)。男、女性别HBV均以C基因型占优势,分别为57.3%和54.5%,性别间无统计学差异(P>0.05);年龄<30岁组HBV以B基因型(40.3%)、C基因型(51.7%)占优势,≥30岁组以C基因型(67.2%)占优势,<30岁组B基因型构成比高于≥30岁组(29.6%,P<0.05);HCC、LC患者中HBV以C基因型为主,分别占73.0%和75.6%。BCP双突变率在HCC、LC分别为64.9%和56.8%;HBVC基因型多发生BCP双突变,占63.6%(42/66)。结论鲁南地区HBV基因型以C型和B型为主,其中LC、HCC患者基因型以C型占优势,HCC患者BCP双突变率显著高于CHB患者,在慢性HBV感染者中HBVC基因型多发生BCP双突变。     

Case-control study of hepatitis B virus infection in chronic liver disease and hepatocellular carcinoma

Summary The prevalence of serum hepatitis B virus markers was studied in three groups of age- and sex-matched patients:a. 31 patients with liver cirrhosis and hepatocellular carcinoma (c-HCC);b. 31 patients with chronic liver disease (CLD) andc. 62 hospitalized control subjects. The overall exposure rate to the hepatitis B virus was 90% in c-HCC, 80% in CLD and 58% in control subjects. The prevalence of hepatitis B surface antigen (HBsAg) was 29%, 13% and 1.6% in the three groups, respectively. The prevalence of hepatitis B surface antibody was significantly lower in c-HCC (9.6%) than CLD (42%) and control subjects (40%). The serological evidence of continuous viral replication (HBsAg positivity or isolated high titre hepatitis B core antibody positivity) was more common in c-HCC (39%) than CLD (12%) and control subjects (1.6%). The prevalence and patterns of aggregation of serum hepatitis B virus markers were similar in the 31 patients with c-HCC and in 11 patients with HCC without concomitant liver cirrhosis (n-HCC). In conclusion, the overall exposure rate to the hepatitis B virus is similar in c-HCC and CLD. However, serological evidence of continuous viral replication is more common in the former group. A defective clearance of the hepatitis B virus in hepatocellular carcinoma is a possible explanation of the phenomenon. The strength of the association between hepatitis B virus infection and hepatocellular carcinoma appears to be similar in c-HCC and n-HCC.     

不同乙型肝炎病毒DNA载量对乙型肝炎相关性肝细胞癌患者肝功能的影响

目的:分析不同乙型肝炎病毒DNA(hepatitis B virus DNA,HBV DNA)载量对乙型肝炎病毒相关性肝细胞癌患者手术后肝功能的影响。方法:选择2017年2月至2018年8月在广西科技大学第二附属医院78例行肝癌根治术的肝细胞癌患者的临床资料进行回顾性分析。根据术前血清HBV DNA载量差异,分为高拷贝...     

Present status of hepatitis virus-associated hepatocellular carcinoma in Nagasaki Prefecture, Japan: a cross-sectional study of 1019 patients

The present study was designed to determine the frequency of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in patients with hepatocellular carcinoma (HCC) in Nagasaki Prefecture, Japan. We examined the clinical features of 1019 patients with HCC who visited our hospitals between January and December 1999. The ratio of men to women was 709 : 310, and the peak incidence of HCC was in the seventh decade of life in both men and women. In the majority of the patients, HCC showed association with HCV infection (74%) compared with HBV infection (17%). HBV-associated HCC was more common in young patients, while HCV-associated HCC was more common in patients with a history as a "daily drinker", or with a history of blood transfusion, liver cirrhosis, and persistently high serum transaminases before the diagnosis of HCC. HCC was initially suspected by ultrasonography or computed tomography in 776 of the 874 patients for whom there was a history of mode of detection of HCC (89%). Tumor size at the time of diagnosis of HCC in patients who had been regularly followed up for liver diseases at our hospitals was significantly smaller than that in patients who were not followed up regularly before the diagnosis (P < 0.01). Our results indicate that the proportions of patients with HBV or with HCV infection among HCC patients in Nagasaki Prefecture are similar to those found in a nationwide survey in Japan, and there are some differences between the clinical manifestations of HBV- and HCV-associated HCC. Our results emphasize the importance of close follow-up for the high-risk group (i.e. those with HBV- or HCV-associated chronic liver diseases) for the early detection of HCC. Received: July 18, 2001 / Accepted: September 17, 2001     

Extremely high titer of hepatitis B surface antigen antibodies in a primary hepatocellular carcinoma patient: A case report

BACKGROUNDHepatocellular carcinoma (HCC) may be caused by hepatitis B virus (HBV) infection. Post-infection recovery-associated changes of HBV indicators include decreased hepatitis B surface antigen (HBsAg) level and increased anti-HBsAg antibody titer. Testing to detect HBV DNA is conducted rarely but could detect latent HBV infection persisting after acute infection and prompt administration of treatments to clear HBV and prevent subsequent HBV-induced HCC development. Here, we present an HCC case with an extremely high anti-HBsAg antibody titer and latent HBV infection.CASE SUMMARYA 57-year-old male patient with abdominal pain who was diagnosed with primary HCC presented with an extremely high level (over 2000 ng/mL) of serum alpha-fetoprotein. Abdominal B-ultrasonography and computed tomography scan results indicated focal liver lesion and mild splenomegaly. Assessments of serological markers revealed a high titer of antibodies against hepatitis B core antigen (anti-HBcAg antibodies), an extremely high titer (1000 mIU/mL) of hepatitis B surface antibodies (anti-HBsAg antibodies, anti-HBs) and absence of detectible HBsAg. Medical records indicated that the patient had reported no history of HBV vaccination, infection or hepatitis. Therefore, to rule out latent HBV infection in this patient, a serum sample was collected then tested to detect HBV DNA, yielding a positive result. Based on the aforementioned information, the final diagnosis was HCC associated with hepatitis B in a compensated stage of liver dysfunction and the patient was hospitalized for surgical treatment.CONCLUSIONA rare HCC case with high serum anti-HBsAg antibody titer and detectable HBV DNA resulted from untreated latent HBV infection.     

Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients

Chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) is a major health problem in Asian-Pacific regions. Antiviral therapy reduces, but does not completely prevent, HCC development. Thus, there is a need for accurate risk prediction to assist prognostication and decisions on the need for antiviral therapy and HCC surveillance. A few risk scores have been developed to predict the occurrence of HCC in CHB patients. Initially, the scores were derived from untreated CHB patients. With the development and extensive clinical application of nucleos(t)ide analog(s) (NA), the number of risk scores based on treated CHB patients has increased gradually. The components included in risk scores may be categorized into host factors and hepatitis B virus factors. Hepatitis activities, hepatitis B virus factors, and even liver fibrosis or cirrhosis are relatively controlled by antiviral therapy. Therefore, variables that are more dynamic during antiviral therapy have since been included in risk scores. However, host factors are more difficult to modify. Most existing scores derived from Asian populations have been confirmed to be accurate in predicting HCC development in CHB patients from Asia, while these scores have not offered excellent predictability in Caucasian patients. These findings support that more relevant variables should be considered to provide individualized predictions that are easily applied to CHB patients of different ethnicities. CHB patients should receive different intensities of HCC surveillance according to their risk category.     

Incident hepatocellular carcinoma developing during tenofovir alafenamide treatment as a rescue therapy for multi-drug resistant hepatitis B virus infection: A case report and review of the literature

Tenofovir disoproxil fumarate (TDF) is a potent nucleotide analogue with high barrier to resistance, which is recommended for multi-drug resistant hepatitis B virus (HBV) infection. However, nephrotoxicity has been reported during TDF treatment, and tenofovir alafenamide (TAF), which has comparable efficacy to TDF and improves bone and renal safety, can be used as a replacement strategy. Herein, we describe a clinical case concerning a 60-year-old individual suffering liver cirrhosis and renal dysfunction, and being infected with multidrug-resistant HBV. When failing treatment with TDF, he received TAF as a rescue therapy. TAF effectively inhibited HBV replication without worsening renal function or serum phosphorus abnormality. Furthermore, hepatocellular carcinoma (HCC) occurred during TAF treatment despite controlling the viral load. The risk of HCC could not be eliminated and should be monitored during TAF treatment.